1.12
-0.05(-4.27%)
Currency In USD
| Previous Close | 1.17 |
| Open | 1.15 |
| Day High | 1.16 |
| Day Low | 1.11 |
| 52-Week High | 1.69 |
| 52-Week Low | 0.75 |
| Volume | 303,090 |
| Average Volume | 516,151 |
| Market Cap | 41.04M |
| PE | -2.95 |
| EPS | -0.38 |
| Moving Average 50 Days | 1.15 |
| Moving Average 200 Days | 1.17 |
| Change | -0.05 |
If you invested $1000 in RenovoRx, Inc. (RNXT) since IPO date, it would be worth $154.27 as of October 19, 2025 at a share price of $1.12. Whereas If you bought $1000 worth of RenovoRx, Inc. (RNXT) shares 3 years ago, it would be worth $618.78 as of October 19, 2025 at a share price of $1.12.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD
GlobeNewswire Inc.
Oct 09, 2025 12:30 PM GMT
Leading Expert on Targeted Drug-Delivery and Locoregional Cancer Therapies Strengthens RenovoRx’s Scientific Advisory BoardLOS ALTOS, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life scie
RenovoRx’s PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites
GlobeNewswire Inc.
Sep 25, 2025 12:30 PM GMT
First Registry-Eligible Patient Procedure Commenced at the University of Vermont Cancer Center Baptist Health Miami Cancer Institute and University of Pittsburgh Medical Center Join the University of Vermont Cancer Center as Participating Clinical Si
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th
GlobeNewswire Inc.
Sep 11, 2025 12:30 PM GMT
MOUNTAIN VIEW, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleare